Ødegaard, Kristina Malene
Lirhus, Sandre Svatun
Melberg, Hans Olav
Hallén, Jonas
Halvorsen, Sigrun
Funding for this research was provided by:
Norges Forskningsråd
Novartis Norway AS
Article History
Received: 14 April 2021
Accepted: 21 February 2022
First Online: 5 March 2022
Declarations
:
: The protocol conforms to the principles outlined in the Declaration of Helsinki. The Regional Committee for Medical and Health Research Ethics (REK) approved this study (2017/1243) and waivered the requirement of informed consent.
: Not applicable.
: KMO is a PhD-student at the University of Oslo and an employee of Novartis Norway AS. JH was an employee of Novartis Norway AS at the time the study was conducted. SH reports speakers’ honoraria from Bayer, Pfizer/Bristol Myers Squibb, Sanofi, outside the submitted work. SSL and HOM report consultancy fees from Novartis during the conduct of the study; personal fees from Novartis and Takeda, outside the submitted work.